LPA and atherosclerosis: Phase 3 of the lp(a)-HORIZON study enrolled 8323 patients with ASCVD and elevated baseline Lp(a) levels (>70 mg/dL) and evaluated the reductions in Lpa and MACE with pelacarsen.